MarketCap
Facebook
X
Telegram
AcelRx Pharmaceuticals Operating Cycle | ACRX
Annual Operating Cycle AcelRx Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 117 | 48.3 | 185 | 141 | 260 | 146 | 103 | 187 | 158 | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 260 | 48.3 | 149 |
Quarterly Operating Cycle AcelRx Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 221 | 145 | 161 | - | 310 | 201 | 249 | - | 123 | 128 | 275 | 83 | 205 | 208 | 237 | 7.29 | 101 | 110 | 285 | 189 | 137 | 77.2 | 142 | 82.7 | 158 | 117 | 138 | 173 | 19.4 | 156 | 828 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 828 | 7.29 | 182 |
Operating Cycle of other stocks in the Drug manufacturers industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
TherapeuticsMD
TXMD
|
3.34 K | $ 1.74 | 2.96 % | $ 20.1 M |  USA |
 |
Assertio Holdings
ASRT
|
590 | - | - | $ 150 M | USA |
 |
Jupiter Wellness
JUPW
|
132 | - | - | $ 33.6 M | USA |
 |
ProPhase Labs
PRPH
|
982 | - | - | $ 5.07 M | USA |
 |
Zomedica Corp.
ZOM
|
218 | - | -0.21 % | $ 98 M | USA |
 |
Agile Therapeutics
AGRX
|
146 | - | 10.11 % | $ 58.2 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
416 | - | - | $ 2.06 B |  France |
 |
Pacira BioSciences
PCRX
|
399 | $ 36.48 | 0.04 % | $ 1.63 B | USA |
 |
Perrigo Company plc
PRGO
|
201 | $ 16.83 | -0.71 % | $ 2.33 B | USA |
 |
Evoke Pharma
EVOK
|
55.1 | - | - | $ 36.6 M | USA |
 |
Tilray
TLRY
|
221 | $ 2.66 | -6.84 % | $ 297 M |  Canada |
 |
Aerie Pharmaceuticals
AERI
|
576 | - | - | $ 754 M | USA |
 |
Veru
VERU
|
271 | $ 2.12 | -3.2 % | $ 31.1 M | USA |
 |
Viatris
VTRS
|
221 | $ 20.86 | 1.81 % | $ 23.9 B | USA |
 |
Alimera Sciences
ALIM
|
181 | - | - | $ 142 M | USA |
 |
cbdMD
YCBD
|
152 | $ 0.39 | 1.86 % | $ 1.57 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
121 | - | 0.86 % | $ 117 M | USA |
 |
China Pharma Holdings
CPHI
|
187 | $ 0.55 | -2.64 % | $ 2.36 M |  China |
 |
Lannett Company
LCI
|
210 | - | 1.15 % | $ 7.11 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
14.6 K | - | - | $ 55.5 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
214 | - | -39.89 % | $ 27.7 M | USA |
 |
PetIQ
PETQ
|
108 | - | 1.64 % | $ 400 M | USA |
 |
DURECT Corporation
DRRX
|
653 | - | - | $ 50.1 M | USA |
 |
Athenex
ATNX
|
247 | - | -23.39 % | $ 1.76 M | USA |
 |
PLx Pharma
PLXP
|
113 | - | -27.8 % | $ 2.56 M | USA |
 |
Catalent
CTLT
|
152 | - | - | $ 11.5 B | USA |
 |
Endo International plc
ENDP
|
180 | - | - | $ 28.9 M |  Irlanda |
 |
OptiNose
OPTN
|
601 | - | - | $ 1.08 B | USA |
 |
Radius Health
RDUS
|
239 | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
112 | - | -4.76 % | $ 65.3 M | USA |
 |
Canopy Growth Corporation
CGC
|
226 | $ 0.59 | -5.37 % | $ 176 M | Canada |
 |
Aurora Cannabis
ACB
|
1.45 K | $ 5.11 | -1.07 % | $ 280 M | Canada |
 |
Harrow Health
HROW
|
153 | $ 30.4 | 10.67 % | $ 1.12 B | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
662 | $ 5.39 | 0.37 % | $ 80.1 M | USA |
 |
Emergent BioSolutions
EBS
|
425 | $ 6.04 | -0.98 % | $ 323 M | USA |
 |
Cronos Group
CRON
|
931 | $ 3.43 | -3.25 % | $ 1.32 B | Canada |
 |
Evolus
EOLS
|
134 | $ 6.81 | -2.51 % | $ 439 M | USA |
 |
Organogenesis Holdings
ORGO
|
159 | $ 0.96 | 5.83 % | $ 122 M | USA |
 |
Bausch Health Companies
BHC
|
79.8 | $ 8.33 | -0.83 % | $ 3.09 B | Canada |
 |
OrganiGram Holdings
OGI
|
2.92 K | $ 0.85 | -2.69 % | $ 81 M | Canada |
 |
Rockwell Medical
RMTI
|
72.5 | $ 7.35 | -2.26 % | $ 264 M | USA |
 |
SCYNEXIS
SCYX
|
33.1 | $ 3.54 | 1.14 % | $ 177 M | USA |
 |
HEXO Corp.
HEXO
|
775 | - | 2.45 % | $ 38.1 M | Canada |